The funds will be used for the layout of laboratory animal resource bases and laboratories
Laboratory animal research service provider Lingfu Bio (Chinese:灵赋生物) recently completed an over CNY200 million (USD 30.52 million) pre-Series A financing round led by China Life Equity Investment and Legend Capital; Chang Development, Puhua Capital, Safe Pharmaceutical also took apart. Probe Capital served as the financial advisor.
Previously, the company has completed nearly CNY 50 million in its angel financing round.
Beijing Lingfu Biotechnology is co-incubated in 2021 by several well-known companies and laboratory animal industry expert teams such as Safe Pharmaceutical and RenGene Biotech. It is committed to becoming the first scientific research service provider in China that enables life science innovation by integrating the entire industrial chain of experimental animals, animal models and high value-added scientific research services.
With a team of industry experts, along with high-quality animal resource guarantee capabilities, leading large animal model service capabilities and scientific research service technology, Lingfu Bio has the potential to be the next giant in the laboratory animal industry.
At present, Lingfu Bio has deployed the Yangtze River Delta experimental beagle and marmoset resource base, Hainan experimental cynomolgus monkey and miniature pig animal resource base, which are used for the breeding of main experimental animals, conservation breeding, import substitution, and creating a high-quality industrial chain.
It is noteworthy that the company's technical team has strong technical strength in animal disease model modelling, and has rich experience in gene editing modelling and surgical modelling, especially in the field of large animal modelling.
“The demand for experimental animals and model animals continues to grow rapidly in recent years, while the production capacity of large animal models in China is relatively scarce. We expect Lingfu Bio to quickly cover the entire industrial chain and become the most comprehensive provider of high-quality experimental animal resources and featured animal models in China," said Wang Jianfei, managing director of Legend Capital.
The main competitors of Lingfu Bio include Slac Laboratory Animal, Gem Pharmatech (688046:SH), HFK Bio and Shanghai Model Organisms.